MedTrace Logo

Induction of Cytokines in Human Monocytes by SARS-CoV in Adults and Children

NCT00173563 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 10

Last updated 2007-12-03

No results posted yet for this study

Summary

Severe acute respiratory syndrome (SARS) is a new emerging infectious disease. Its pathogen is a newly discovered coronavirus (SARS-CoV). The clinical course can be classified to 3 stages: viral replication phase, hyperimmune reactive phase, and pulmonary destruction phase. Human monocyte plays a critical role in the initiation of immune response in defending the intracellular pathogens (eg viruses). Monocytes can engulf viruses and present the viral antigens in the major histocompatibility (MHC) molecule to the cell surface to initiate T lymphocyte response. Monocytes also secrete various cytokines to modulate immune response. SARS-CoV is a mutant of animal virus to cause human disease and is able to cause unusual severe respiratory illness. It is suggested the unusual severe disease is due to the intense immune reaction.

The investigators will harvest human monocytes from healthy adult and children blood donors. Monocytes would be cultured and infected by SARS-CoV. The change of viral load is monitored after infection. Cytokines secreted by monocytes after infection are also measured. The difference of monocyte cytokine secretion is compared between adults and children. The study is to verify the SARS-CoV infectivity of human monocytes and prove the unusual severity caused by SARS-CoV is related to viral-induced dysregulation of cytokine responses. The results may also clarify why adults tend to have a more severe illness compared with children.

Conditions

  • Healthy

Sponsors & Collaborators

  • National Science and Technology Council, Taiwan

    collaborator OTHER_GOV

  • National Taiwan University Hospital

    lead OTHER

Principal Investigators

  • Luan-Yin Chang, MD, PhD · Department of pediatrics, National Taiwan University Hospital

Eligibility

Min Age
2 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2005-01-31
Completion
2005-09-30

Countries

  • Taiwan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00173563 on ClinicalTrials.gov